Octreotide controlled release

Drug Profile

Octreotide controlled release

Alternative Names: CAM-2029; Octreotide chloride controlled release; Octreotide sc depot

Latest Information Update: 27 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Camurus
  • Developer Camurus; Novartis
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acromegaly; Neuroendocrine tumours

Most Recent Events

  • 01 Apr 2017 Pharmacokinetics and adverse events data from a phase II trial in Acromegaly and Neuroendocrine tumours presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 14 Jul 2016 Novartis and Camurus plan phase III trials for Acromegaly and Neuroendocrine tumours
  • 12 Jul 2016 Camurus completes a phase II trial in Acromegaly and Neuroendocrine tumours in Germany, Sweden, France and Italy (NCT02299089)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top